quality (not dirty) medicines - the way ahead for indian pharma
Post on 07-Jun-2015
63 Views
Preview:
TRANSCRIPT
IMPROVING CONSUMER INTERFACE OF PHARMACEUTICAL & PRIVATE HEALTHCARE
CHIRANTAN CHATTERJEE (IIM-BANGALORE)
DEC 5TH 2013IIMB-CUTS CAPACITY BUILDING WORKSHOP IN PHARMA/HEALTHCARE
2
Indian Pharma-Industry is @ a Cross-Road
3
Indian Pharma-Industry is @ a Cross-Road
Extracts from a recent conversation with a friend
XYZ: playing the balancing gameIndian pharma doesn't look very conducive to consulting right now
29/11/2013 19:17Chirantan Chatterjee why do you say so?
29/11/2013 19:50XYZ: struggling to break through - thats why...
29/11/2013 21:19Chirantan Chatterjee unclear yet..but what happened 'right now' - such that
'breaking through' is becoming difficult...maybe i can offer some suggestions..Saturday
30/11/2013 11:59XYZ: what will sell now, is GMP remedial services... to get the vilified facilities
approved by USFDA and warnings removed - not our cup of tea
4
So why is London Bridge Falling Down?
My argument is because:
We are callous about our own public health, charity after all begins at home. “Why is it acceptable for us to have a very qualified and extremely competent Governor of
the Reserve Bank of India, an institution that oversees monetary policy and not for the
institution that is responsible for public health of a country of over a billion people? Is public
health not half as important as fiscal health for us? “
3 standards for ‘regulated’ / ‘semi-regulated’/ ‘domestic markets’ – why?
Perennially seduced by the ‘jugaad attitude’.
Absence of evidence-based regulation: “Do we have any data that tells us how many times a particular prescription has been
changed because of drug-drug interactions? Many of our elderly take more than one drug
today, perhaps one for controlling their blood pressure, another one to control their sugar
levels and perhaps a third one for their arthritis. We have no data to assess how these
formulations (remember, I am saying formulations, manufactured according to the
standards for “less regulated” markets) behave in our patient population. “
5
Could Consumers Change the Status-Quo? – Global Examples
Public health outreach ala CDC-US for flu-shots.
Use Social Media – Check out www.patientslikeme.com.
Regulators could educate consumers – NICE in UK great
example: www.nice.org.uk
Could the Mediplus-es of the world play a role ala
Walmart/CVS? http://
www.walgreens.com/health/health_info.jsp
How about Providers?
http://www.mayoclinic.com/health-information/
Some upcoming examples www.reviews42.com but not nearly
enough.
6
Pharmaceutical Trojans in our communities?
7
E-Governance & Good Work by Some State-FDCAs, Notably Gujarat
Web Portal Link
FDCA’s Web site http://gujhealth.gov.in/food_drug
Sales License Software http://xlnfda.guj.nic.in
Manufacturing License Software – For Manufacturer http://idmla.guj.nic.in
Manufacturing License Software – For FDCA Officers http://dmla.guj.nic.in
Online Complaint Module http://gujhealth.gov.in/complaint
Transparent & hassle free procedures
SMS intim
ation
Hassle free pro
cedureNo chance of
corrupt practices
SMS-Based Drug Recall System – Working Great
SMS Alerts
Effectiv
e recall
Benefits to Business Community
SMS-Based Drug Recall System – Working Great
Mobile Testing Labs
11
Peer Effects Created on Other States
XLN – GUJARAT MODELOPERATIONAL
PROPOSED
XLN – GUJARAT MODELTOTAL
6 + 6 = 12 STATES COVERING MORE THAN 65% AREA OF COUNTRY
Other States intergration
12
CDSCO Has an Important Role to Play
When is the next report coming out please?
13
Whistle Blower Schemes – Need to Be Sharpened
14
Differences Across Regions – Need to be Minimized
Bhaskarabhatla, Chatterjee & Karreman (2013)
15
Differences Across Regions – Need to be Minimized
Who Will Bell the Cat?
16
Residual aspects
Cocktail drugs & their prescribing behavior needs oversight.
The Role of Oversight on Pharmaceutical Promotions? Role of
IMA
The Key Role of State-Owned Public Sector Units to create
benchmark Quality standards.
Medical devices continue sales unmonitored.
Price dispersion in healthcare services:
The same knee-replacement surgery in a city could vary in
prices but is that price a signal of quality?
What rights do we have to demand information on quality?
17
Departing Remarks
How long are we going to be afraid to look at what is
wrong?
A true patriot says “we can do better”; a false patriot on
the other hand says “we are good enough”.
We need to move to ‘Quality Medicines’ – not ‘Dirty
Medicines’.
Thank you.
18
Questions?
Email: chirantan.chatterjee@iimb.ernet.in
top related